Table 3.

Studies primarily focusing on SGLT2 inhibitor (SGLT2i) use in Ramadan. The number in the parenthesis is reference

No	Drug (SGLT2 inhibitor)	Trial	Main findings
1.	Dapagliflozin [51]	Switching from SU to SGLT2i in Ramadan fasting. Both arms have metformin	Fewer patients exhibited hypoglycaemia for dapagliflozin vs SU
2.	Canagliflozin [52]	Canagliflozin in Ramadan Tolerance Observational Study	Support use of canagliflozin for T2D adults during Ramadan fasting as less episodes of hyopglycaemia
3.	Canagliflozin 100 mg or Dapagliflozin 10 mg [53]	Safety SGLT2i during Ramadan for Muslim T2D	Use of insulin with SGLT2i increases hypoglycaemia risk during Ramadan Mild hypo not needing hospitalisation Careful monitoring during prolonged fasting No effect on renal function
4.	Any drug and dose of SGLT2 inhibitor [54]	The effect of Ramadan fasting and continuing SGLT2i on ketonemia, BP and renal function in Muslim patients with T2D	non- significant changes in weight, BP and eGFR regardless of SGLT2i with no increase in ketonemia, eGFR deterioration or hypoglycemia
5.	Drug not specified [55]	Use of Flash Glucose Monitoring System (FGMS) in SGLT2i during Ramadan fasting in high risk insulin treated T2D	Use of SGLT2i with insulin during Ramadan using FGMS in high-risk patients with T2D under optimal care There was minimal interruption of fasting, significant improvement in glycemic control and no significant change in kidney function after Ramadan

SU = sulphonylurea